According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below:
Green Mountain Coffee (NASDAQ:GMCR): Director Robert P. Stiller sold 5,000,000 Shares
Director of Green Mountain Coffee (NASDAQ:GMCR) Robert P. Stiller sold 5,000,000 shares on 05/07/2012 at an average price of $25.34.
Green Mountain Coffee Roasters engages in the production and marketing of award-winning coffees, innovative brewing technology and gourmet single-cup brewing systems. Green Mountain Coffee has a market cap of $7.55 billion; its shares were traded at around $25.34 with a P/E ratio of 23.9 and P/S ratio of 2.9. Green Mountain Coffee had an annual average earnings growth of 32.9% over the past 10 years. GuruFocus rated Green Mountain Coffee the business predictability rank of 2.5-star.
On May 2 Green Mountain Coffee Roasters Inc. announced its second quarter fiscal year 2012 results for the thirteen and twenty-six weeks ended March 24, 2012. Net sales of $885.1 million, up 37% over net sales of $647.7 million in the year-ago quarter.
Director Vecchio Jules A. Del sold 20,000 shares of GMCR stock on 02/27/2012 at the average price of $66.93. Vecchio Jules A. Del owns at least 240,719 shares after this. The price of the stock has decreased by 62.14% since.
Vertex Pharm (NASDAQ:VRTX): Executive Vice President and Chief Commercial Officer Nancy Wysenski sold 185,704 Shares
Executive Vice President and Chief Commercial Officer of Vertex Pharm (NASDAQ:VRTX) Nancy Wysenski sold 185,704 shares on 05/08/2012 at an average price of $62.02.
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex Pharm has a market cap of $7.89 billion; its shares were traded at around $62.02 with a P/E ratio of 41.2 and P/S ratio of 5.6.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2012.
On April 26 Vertex reported total first quarter 2012 revenues of approximately $439 million, including net product revenues of approximately $357 million from INCIVEK®(telaprevir) and approximately $18 million from KALYDECOTM (ivacaftor).
Executive Vice President Global R&D, CSO Peter Mueller sold 79,500 shares of VRTX stock on 05/07/2012 at the average price of $53.03. Peter Mueller owns at least 152,603 shares after this. The price of the stock has increased by 16.95% since.
Cerner Corp. (NASDAQ:CERN): Vice Chairman Clifford W. Illig sold 120,000 Shares
Vice Chairman of Cerner Corp. (NASDAQ:CERN) Clifford W. Illig sold 120,000 shares on 05/04/2012 at an average price of $79.92.
Cerner Corp. designs, develops, markets, installs and supports information technology and content solutions for healthcare organizations and consumers that are capable of being implemented on an individual, combined or enterprise-wide basis and are accessible over the internet by consumers, physicians and healthcare providers. Cerner Corp. has a market cap of $12.53 billion; its shares were traded at around $79.92 with a P/E ratio of 38.7 and P/S ratio of 5.7. Cerner Corp. had an annual average earnings growth of 17.3% over the past 10 years. GuruFocus rated Cerner Corp. the business predictability rank of 4.5-star.
On April 26, 2012, Cerner Corporation announced results for the 2012 first quarter that ended March 31, 2012, delivering strong levels of bookings, revenue, earnings and cash flow. Bookings in the first quarter of 2012 were $652.3 million, an all-time high for a first quarter and an increase of 24 percent compared to first quarter 2011 bookings of $524.9 million.
Allergan Inc. (NYSE:AGN): Executive Vice President Finance and Business Development and CFO Jeffrey L. Edwards sold 99,462 Shares
Executive Vice President Finance and Business Development and CFO of Allergan Inc. (NYSE:AGN) Jeffrey L. Edwards sold 99,462 shares on 05/04/2012 at an average price of $92.97.
Allergan Inc. is a provider of eye care and specialty pharmaceutical products throughout the world with products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets. Allergan Inc. has a market cap of $29.37 billion; its shares were traded at around $92.97 with a P/E ratio of 26.4 and P/S ratio of 5.4. The dividend yield of Allergan Inc. stocks is 0.2%. Allergan Inc. had an annual average earnings growth of 14.9% over the past 10 years.
On May 2, Allergan Inc. announced operating results for the quarter ended March 31, 2012. Allergan also announced that its Board of Directors has declared a first quarter dividend of $0.05 per share, payable on June 14, 2012 to stockholders of record on May 24, 2012. Allergan reported $0.74 diluted earnings per share attributable to stockholders compared to $0.51 diluted earnings per share attributable to stockholders for the first quarter of 2011.
Senior Vice President and Corporate Controller (PAO) James F. Barlow sold 4,925 shares of AGN stock on 03/13/2012 at the average price of $93.19. James F. Barlow owns at least 10,418 shares after this. The price of the stock has decreased by 0.24% since.
For the complete list of stocks that bought/sold by their company executives, go to: Insider Buys.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.